GLP-2 is a 33-amino-acid peptide hormone derived from proglucagon. Research centers on its effects in the intestine: mucosal growth, nutrient absorption and barrier function. It is a different research target from GLP-1, which acts on insulin release and glucose control. This guide covers what the literature reports, where the clinical data comes from, which safety signals are documented, and what Australian researchers should check before sourcing.
TL;DR
- GLP-2 is produced by intestinal L cells and signals through the GLP-2 receptor (GLP-2R), a class B1 GPCR coupled to Gαs and cAMP.
- Main reported effects: increased villus height, higher absorptive surface, improved barrier function, greater nutrient uptake.
- Clinical evidence comes mainly from GLP-2 analogs (teduglutide, apraglutide) in short bowel syndrome, not from native GLP-2.
- Rodent carcinogenicity and tumor-promotion data exist and belong in any study design.
- Sourcing in Australia requires checking the therapeutic goods and Poisons Standard status of each compound.
Table of Contents
- What GLP-2 is
- GLP-2 vs GLP-1
- Receptor biology and signaling
- Reported effects in the intestine
- Nutrient absorption and energy metabolism
- Clinical evidence: short bowel syndrome
- Safety signals documented in the literature
- Study design points for GLP-2 work
- Sourcing GLP-2 research material in Australia
- Perspective
- Related compounds in the catalogue
- Order research-grade peptides
- FAQ
- Sources
What GLP-2 is
GLP-2 corresponds to amino acids 126 to 158 of proglucagon. Enteroendocrine L cells in the small and large intestine secrete it in response to nutrients. The 2025 Physiological Reviews review of proglucagon-derived peptides describes this origin and the native form, GLP-2(1–33), as the full agonist of the receptor.
The same review reports that the truncated form GLP-2(3–33) acts as an antagonist of the native peptide. At high doses it is also a partial agonist, producing roughly 15 to 20% receptor activation. This matters when interpreting antagonist experiments.
GLP-2 and GLP-1 are cleaved from the same precursor and co-secreted. Their functions diverge.
GLP-2 vs GLP-1
| Feature | GLP-1 | GLP-2 |
|---|---|---|
| Precursor | Proglucagon | Proglucagon |
| Source | Intestinal L cells | Intestinal L cells |
| Insulin release | Stimulated | Not modulated |
| Glucose homeostasis | Lowers plasma glucose | No significant direct influence |
| Main reported action | Glucose-dependent insulin secretion | Intestinal growth, repair, nutrient uptake |
Per the Colorado State University enteroglucagon reference, GLP-2 does not modulate insulin release or significantly affect glucose homeostasis. Its predominant effects are on intestinal growth and repair, anti-inflammatory action and stimulation of nutrient uptake by epithelial cells.
Researchers working on the incretin side of metabolism will find related background in our guide to GIP peptide function.
Receptor biology and signaling
The GLP-2 receptor is a 550-amino-acid, seven-transmembrane GPCR in class B1. It was cloned from hypothalamic and intestinal cDNA libraries in 1999. According to the Physiological Reviews review:
- Signaling runs through Gαs, with cAMP accumulation on activation.
- The receptor recruits beta-arrestins.
- It internalizes from the cell surface by beta-arrestin-dependent and beta-arrestin-independent mechanisms.
Cell types and indirect mediators
In mice, GLP-2R is detected in subepithelial myofibroblasts. The same source reports that GLP-2 raises intestinal IGF-I expression and secretion. IGF-I is required for GLP-2-induced crypt-cell proliferation, and that proliferation is lost in IGF-I knockout mice. Part of the GLP-2 effect is therefore indirect, which affects assay design: readouts of crypt proliferation depend on an intact IGF-I axis. For the wider pathway context, see our mechanistic review of IGF-1 metabolic pathways.
Reported effects in the intestine
The 2025 review summarizes GLP-2 actions as follows:
- Increased cell proliferation with inhibited apoptosis.
- Greater villus height and expanded absorptive mucosal surface.
- Higher capacity for carbohydrate, amino acid and lipid absorption.
- Enhanced gut barrier function.
- Stimulated intestinal blood flow.
- Inhibited gastrointestinal motility.
A 2004 study in a neonatal model is among the work ranked for this topic, and rat studies report increased stomach and small intestine weight and length with GLP-2 exposure during lactation. These growth effects explain why the peptide is described as intestinotrophic.
Nutrient absorption and energy metabolism
Keyword searches often pair GLP-2 with metabolism. The literature supports a specific reading: GLP-2 affects nutrient absorption, not insulin signaling.
- Brush-border enzymes and transporters. A 2002 review in Gut reports that GLP-2 increases the activity of epithelial digestive enzymes and nutrient transporters. Stimulation of intestinal hexose transport is the most rapid action described: detectable within 30 minutes of infusion and maximal by 60 minutes.
- GLUT2 trafficking. A 2018 study on T1R2 receptor-mediated glucose sensing describes GLP-2 potentiating glucose absorption in enterocytes. In response to a glucose-rich meal, co-secreted GLP-1 potentiates insulin secretion and counterbalances the rise in plasma glucose.
- Human energy balance. In a phase 1 and 2 metabolic balance trial, once-weekly 5 mg apraglutide increased intestinal wet weight absorption by 741 g/day and energy absorption by 1095 kJ/day (95% CI 196 to 1994; P=0.024). Carbohydrate absorption rose by 518 kJ/day and lipid absorption by 376 kJ/day.
For a study of body composition or adipose biology, these data frame GLP-2 as a modulator of energy uptake. Our overview of peptides in adipose tissue research covers the tissue side.
Clinical evidence: short bowel syndrome
Most human data come from teduglutide, a GLP-2 analog. The native peptide has a short half-life, so analogs were developed for clinical use.
STEPS trial
The FDA label for Gattex reports the 24-week, randomized, double-blind, placebo-controlled STEPS trial in 86 subjects with intestinal failure due to short bowel syndrome:
| Outcome at week 24 | Teduglutide | Placebo |
|---|---|---|
| Responders | 63% | 30% |
| Mean reduction in parenteral support volume | 32% (4.4 L/week) | 21% (2.3 L/week) |
The responder difference had p=0.002 and the volume difference p=0.03.
Earlier dose-ranging trial
A 24-week randomized trial published in Gut found that 0.05 mg/kg/day significantly reduced parenteral volumes (16/35 responders, p=0.007). The 0.10 mg/kg/day dose did not reach significance (8/32 against 1/16 on placebo, p=0.16). Three treated patients were weaned off parenteral support entirely. Villus height, plasma citrulline and lean body mass rose significantly against placebo.
The non-linear dose response is relevant to any preclinical dose-finding plan.
Regulatory context in Australia
The TGA approved registration of Revestive (teduglutide) for adult short bowel syndrome, as set out in its Australian public assessment report. This is a registered prescription medicine. It is separate from any material labelled for research use.
Safety signals documented in the literature
Safety data should shape protocols from the start.
- Carcinogenicity in rodents. The Gattex label reports that in a 2-year study in Wistar Han rats at 3, 10 and 35 mg/kg/day (about 60, 200 and 700 times the recommended human daily dose), teduglutide increased adenomas of the bile duct and jejunum in males. In CD1 mice, males at the high dose of 12.5 mg/kg/day showed more gall bladder papillary adenomas and jejunal adenocarcinomas.
- Tumor promotion. A review on teduglutide and short bowel syndrome describes mice pretreated with azoxymethane. They showed more and larger aberrant crypt foci with GLP-2, and adenocarcinomas formed almost exclusively in GLP-2-treated animals.
- Adverse events in clinical studies. The same review lists abdominal pain, bloating, constipation, nausea, injection site erythema, lower limb edema, stoma swelling, headache and nasopharyngitis, with no significant increase in serious adverse events.
GLP-2 drives proliferation of intestinal epithelium. Studies involving colonic neoplasia models, or any tissue with existing lesions, call for documented endpoints and ethics oversight.
Study design points for GLP-2 work
- Define the form. GLP-2(1–33) is the full agonist. GLP-2(3–33) is an antagonist with partial agonism at high doses. Record which sequence is used.
- Confirm identity and purity. Request the Certificate of Analysis with HPLC and mass spectrometry data for the exact batch. Match batch numbers to vial labels.
- Plan reconstitution and storage. Follow the supplier's documented guidance, aliquot to limit freeze-thaw cycles and log lot numbers in the lab record.
- Choose readouts that fit the mechanism. Villus height, crypt proliferation, citrulline, hexose uptake and barrier measures reflect the reported biology. Insulin and glucose tolerance endpoints are not primary GLP-2 effects.
- Include an IGF-I component where proliferation is measured. The knockout data show dependence.
- Record safety endpoints. Add histology for neoplastic change in long-duration designs.
Sourcing GLP-2 research material in Australia
Compounds in the GLP-2 class that have therapeutic uses can fall under the Poisons Standard and the Therapeutic Goods Act. Status differs by compound and can change. Before ordering, confirm the current scheduling and any permit, institutional approval or ethics requirement for your use through the TGA and your institution's compliance office. Material labelled for research is not for human or veterinary use.
General procurement checks:
- Batch-specific Certificate of Analysis.
- HPLC purity and mass spec identity.
- Traceable batch documentation.
- Clear labelling as research use only.
- Written shipping and storage terms.
Perspective
At Peptastic Labs we treat documentation as part of the product. For every peptide we supply, we apply in-house checks, third-party verification and batch records. We designed this process to give researchers HPLC-verified material at ≥99% purity, with Certificates of Analysis available on request.
GLP-2 work shows why this matters. The receptor has a full agonist and a partial-agonist antagonist form, the proliferative endpoints are sensitive, and the literature carries safety signals. A study with an uncertain sequence or unknown purity cannot be interpreted against that background. Our position is that identity and purity data should be on file before the first dose-response curve.
We organize our catalogue by research area, from metabolic and tissue repair to longevity, hormone and reproductive, blends and ancillaries and reagents. Researchers can match their program to a category and request batch documentation before ordering.
Tintastic
Related compounds in the catalogue
Researchers studying incretin and metabolic pathways often work across several targets. Our catalogue includes GLP-3 RT 10mg and GLP-3 RT 20mg, supplied at ≥99% purity. For wider reference, see our guides on immune modulation peptides and melanocortin peptides.
Order research-grade peptides
Peptastic Labs supplies independently tested, HPLC-verified research peptides with batch documentation. Bulk and wholesale options are available, and orders can be placed online or through pre-filled Telegram and WhatsApp checkout.
Browse research categories in the Peptastic Labs catalogue or start from the main site. Prices are listed on product pages.
FAQ
What are the benefits of GLP-2 reported in research?
Studies report increased villus height, expanded absorptive mucosal surface, better gut barrier function and higher carbohydrate, amino acid and lipid absorption. In clinical trials of the analog teduglutide, treated short bowel syndrome patients needed less parenteral support than placebo patients. These are research findings, not claims for any product.
What is the difference between GLP-1 and GLP-2?
Both come from proglucagon and are secreted by intestinal L cells. GLP-1 stimulates insulin release and lowers plasma glucose. GLP-2 does not significantly affect insulin or glucose homeostasis and acts mainly on intestinal growth, repair and nutrient absorption.
What are the long-term effects of GLP-2?
Long-term human data on the native peptide are limited. Rodent studies with teduglutide report intestinal and biliary adenomas at high multiples of the human dose, and mouse work shows tumor promotion after carcinogen pretreatment. Clinical studies list mostly gastrointestinal and injection-site adverse events.
Does GLP-2 work for weight loss?
The research does not place GLP-2 in the weight-loss category. It increases intestinal energy absorption, as the apraglutide balance trial shows. Appetite and glucose-lowering research centers on GLP-1 and related incretin targets.
Sources
- Proglucagon-derived peptides: human physiology and pathophysiology (Physiological Reviews, 2025)
- Enteroglucagons (GLP-1, GLP-2, and Others), Colorado State University
- Distinct Identity of GLP-1R, GLP-2R and GIPR (Frontiers, 2021)
- Gut adaptation and the glucagon-like peptides (Gut, 2002)
- T1R2 receptor-mediated glucose sensing in the upper intestine (2018)
- Apraglutide, a once-weekly GLP-2 analog (2022)
- Gattex (teduglutide) FDA label
- Teduglutide in short bowel syndrome, Gut (2011)
- Teduglutide and short bowel syndrome (Dove Press, 2011)
- TGA Australian public assessment report, Revestive